METABOLICA HEALTH INC.

Rewiring Metabolism. Restoring Insulin. Rethinking Diabetes

Advancing microbiome-derived therapeutics for metabolic disease.

At Metabolica Health, we are developing a patent-protected small molecule therapy focused on restoring the body's ability to regulate blood glucose and reduce fat.

Our lead compound, 4-cresol (p-cresol, 4-methylphenol) is a naturally occurring microbial metabolite that:

🔹 Stimulates insulin secretion by regenerating insulin-producing pancreatic β-cells

🔹 Reduces adiposity, liver fat, and improves systemic metabolic balance

🔹 Targets the biological root cause of type 2 diabetes

Backed by peer-reviewed science and global academic collaborations, we're not just developing a drug—we're building a new foundation for metabolic health.

Transformative science. Clinical momentum. Investor-ready.

"Insulin is not a cure for diabetes; it is a treatment. — Sir Frederick Banting

“The future of diabetes and obesity care lies in restoring the body’s own ability to regulate blood glucose.” — Metabolica Health

From Discovery to Translation

A Scalable Platform for Metabolic Disease

Metabolica Health is advancing a first-in-class therapeutic platform based on microbiome-derived small molecules. Our U.S. patent–protected lead candidate, 4-cresol, demonstrates regenerative activity in β-cells, metabolic reprogramming, and systemic benefits in preclinical models of diabetes, obesity, and fatty liver disease (NAFLD/NASH).

✔Patent-backed mechanism distinct from GLP-1s

✔Proof-of-concept published in leading journals such as Cell Reports and PLoS One

✔Global academic partnerships: INSERM, Université Paris Cité (France), Lebanese American University (Lebanon), McGill University (Canada), Kyoto University (Japan)

✔IND-enabling studies in progress

With scientific momentum, regulatory preparation, and platform scalability, Metabolica is positioned to lead the next wave of regenerative metabolic therapies—including diabetes, obesity, and NAFLD/NASH.